Your browser doesn't support javascript.
loading
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
Jonas, Brian A; Wei, Andrew H; Recher, Christian; DiNardo, Courtney D; Jang, Jun-Ho; Pratz, Keith; Panayiotidis, Panayiotis; Montesinos, Pau; Yeh, Su-Peng; Ivanov, Vladimir; Fiedler, Walter; Yamauchi, Takahiro; Duan, Yinghui; Mendes, Wellington; Potluri, Jalaja; Tews, Björn; Ofran, Yishai.
Affiliation
  • Jonas BA; Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.
  • Wei AH; Department of Hematology, The Alfred Hospital and Monash University, Melbourne, Australia.
  • Recher C; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • DiNardo CD; Département d'Hématologie, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Jang JH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pratz K; Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Panayiotidis P; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Montesinos P; Haematology Department and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Yeh SP; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Ivanov V; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Fiedler W; Department of Anesthesiology and Intensive Care, Almazov National Medical Research Center, Saint Petersburg, Russia.
  • Yamauchi T; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Duan Y; Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
  • Mendes W; US Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA.
  • Potluri J; Oncology Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.
  • Tews B; Oncology Clinical Development - Myeloid Program, AbbVie Inc., North Chicago, Illinois, USA.
  • Ofran Y; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA.
Am J Hematol ; 97(8): E299-E303, 2022 08.
Article in En | MEDLINE | ID: mdl-35567776
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Bridged Bicyclo Compounds, Heterocyclic Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Am J Hematol Year: 2022 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Bridged Bicyclo Compounds, Heterocyclic Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Am J Hematol Year: 2022 Document type: Article Affiliation country: United States